-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Nfqe0cZ1KzN7ucFKS05vM+8yc0sbqlmVjeOkkeq55EqOtF3sTGfbGgime9exx4ln
 iQPb1qFgdsSJiRbE8T2+CQ==

<SEC-DOCUMENT>0001209191-08-019500.txt : 20080320
<SEC-HEADER>0001209191-08-019500.hdr.sgml : 20080320
<ACCEPTANCE-DATETIME>20080320155342
ACCESSION NUMBER:		0001209191-08-019500
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20080307
FILED AS OF DATE:		20080320
DATE AS OF CHANGE:		20080320

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AVANT IMMUNOTHERAPEUTICS INC
		CENTRAL INDEX KEY:			0000744218
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				133191702
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
		BUSINESS PHONE:		7814330771

	MAIL ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			021942725

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	T CELL SCIENCES INC
		DATE OF NAME CHANGE:	19920703

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Lorantis Holdings LTD
		CENTRAL INDEX KEY:			0001430324
		STATE OF INCORPORATION:			X0

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-15006
		FILM NUMBER:		08702550

	BUSINESS ADDRESS:	
		STREET 1:		SALISBURY HOUSE, STATION ROAD,
		CITY:			CAMBRIDGE
		STATE:			X0
		ZIP:			CB1 2L
		BUSINESS PHONE:		44 207 932 2100

	MAIL ADDRESS:	
		STREET 1:		SALISBURY HOUSE, STATION ROAD,
		CITY:			CAMBRIDGE
		STATE:			X0
		ZIP:			CB1 2L
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>doc3.xml
<DESCRIPTION>FORM 3 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0202</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2008-03-07</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0000744218</issuerCik>
        <issuerName>AVANT IMMUNOTHERAPEUTICS INC</issuerName>
        <issuerTradingSymbol>AVAN</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001430324</rptOwnerCik>
            <rptOwnerName>Lorantis Holdings LTD</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>SALISBURY HOUSE STATION ROAD</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>CAMBRIDGE</rptOwnerCity>
            <rptOwnerState>X0</rptOwnerState>
            <rptOwnerZipCode>CB1 2L</rptOwnerZipCode>
            <rptOwnerStateDescription>UNITED KINGDOM</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>2811147</value>
                    <footnoteId id="F1"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">The Board of Directors of AVANT Immunotherapeutics, Inc. (&quot;AVANT&quot;), approved a 1-for 12 reverse stock split of AVANT's common stock, which became effective as of March 7, 2008. As a result of the reverse stock split, each twelve shares of AVANT common stock were combined and reclassified into one share of AVANT common stock. The number of shares reported on this form is reflected on a post-split basis. The common stock will trade under the symbol &quot;AVAND&quot; for 20 trading days beginning on March 10, 2008 to designate that it is trading on a post-reverse split basis, and will remain trading under the symbol &quot;AVAN&quot; after the 20-day period has expired.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>Lorantis Holdings Limited

By: /s/ Raj Parekh</signatureName>
        <signatureDate>2008-03-19</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----